Bank of New York Mellon Corp Reduces Stake in Stryker Corporation $SYK

Bank of New York Mellon Corp reduced its position in Stryker Corporation (NYSE:SYK) by 5.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,311,819 shares of the medical technology company’s stock after selling 225,535 shares during the period. Bank of New York Mellon Corp’s holdings in Stryker were worth $1,515,475,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of SYK. Norges Bank purchased a new position in Stryker during the fourth quarter valued at $1,822,272,000. Corient Private Wealth LLC grew its stake in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the period. Alliancebernstein L.P. grew its stake in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares during the period. Strive Asset Management LLC bought a new position in shares of Stryker during the 3rd quarter valued at approximately $227,389,000. Finally, Credit Agricole S A bought a new position in shares of Stryker during the 3rd quarter valued at approximately $194,045,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 2.0%

SYK opened at $293.36 on Wednesday. The firm has a market cap of $112.46 billion, a P/E ratio of 33.95, a P/E/G ratio of 1.89 and a beta of 0.78. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a 50-day moving average of $321.00 and a 200 day moving average of $347.64.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SYK shares. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. Barclays decreased their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. BTIG Research decreased their price target on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Finally, William Blair reissued an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $395.48.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.